515 related articles for article (PubMed ID: 22200324)
21. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
22. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
Sonabend AM; Dana K; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
[TBL] [Abstract][Full Text] [Related]
23. IGFBP2 promotes glioma tumor stem cell expansion and survival.
Hsieh D; Hsieh A; Stea B; Ellsworth R
Biochem Biophys Res Commun; 2010 Jun; 397(2):367-72. PubMed ID: 20515648
[TBL] [Abstract][Full Text] [Related]
24. Glioma stem cell research for the development of immunotherapy.
Xu Q; Yuan X; Yu JS
Adv Exp Med Biol; 2012; 746():216-25. PubMed ID: 22639171
[TBL] [Abstract][Full Text] [Related]
25. Clinical trials with immunotherapy for high-grade glioma.
Ruzevick J; Jackson C; Phallen J; Lim M
Neurosurg Clin N Am; 2012 Jul; 23(3):459-70. PubMed ID: 22748658
[TBL] [Abstract][Full Text] [Related]
26. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
Bambury RM; Morris PG
Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
[TBL] [Abstract][Full Text] [Related]
27. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
28. T-cell immunotherapy for malignant glioma: toward a combined approach.
Dietrich PY; Dutoit V; Tran Thang NN; Walker PR
Curr Opin Oncol; 2010 Nov; 22(6):604-10. PubMed ID: 20739889
[TBL] [Abstract][Full Text] [Related]
29. Deregulated microRNAs identified in isolated glioblastoma stem cells: an overview.
Chu PM; Ma HI; Chen LH; Chen MT; Huang PI; Lin SZ; Chiou SH
Cell Transplant; 2013; 22(4):741-53. PubMed ID: 23127968
[TBL] [Abstract][Full Text] [Related]
30. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of targeting glucose metabolism in glioma stem cells.
Nakano I
Expert Opin Ther Targets; 2014 Nov; 18(11):1233-6. PubMed ID: 25077882
[TBL] [Abstract][Full Text] [Related]
32. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
33. Glioma stem cell research for the development of immunotherapy.
Ji J; Black KL; Yu JS
Neurosurg Clin N Am; 2010 Jan; 21(1):159-66. PubMed ID: 19944974
[TBL] [Abstract][Full Text] [Related]
34. Immunotreatment in patients with glioblastoma multiforme--a histopathological evaluation of reactive and inflammatory changes.
Persson A; Skagerberg G; Salford LG; Englund E;
Clin Neuropathol; 2005; 24(5):201-8. PubMed ID: 16167543
[TBL] [Abstract][Full Text] [Related]
35. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
[TBL] [Abstract][Full Text] [Related]
36. Glioma stem cell signaling: therapeutic opportunities and challenges.
Dietrich J; Diamond EL; Kesari S
Expert Rev Anticancer Ther; 2010 May; 10(5):709-22. PubMed ID: 20470003
[TBL] [Abstract][Full Text] [Related]
37. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
38. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
39. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
[TBL] [Abstract][Full Text] [Related]
40. Nanomedicines Targeting Glioma Stem Cells.
Sabu A; Liu TI; Ng SS; Doong RA; Huang YF; Chiu HC
ACS Appl Mater Interfaces; 2023 Jan; 15(1):158-181. PubMed ID: 35544684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
